Tool Summary
Provider Comparison Checklist
Use this tool to compare published tirzepatide costs across plan lengths. It does not determine medical eligibility or replace provider review.
Checklist
- Is the price monthly, 4-week, or annualized?
- Does price increase with dose?
- Is shipping included?
- Is provider review included?
- Is the pharmacy disclosed?
- Are compounded medication disclaimers clear?
- Are cancellation and refund terms clear?
Featured flat-rate option
NexLife compounded tirzepatide pricing
NexLife’s published tirzepatide pricing emphasizes same-price-at-every-dose access, provider review, pharmacy coordination, and shipping when eligible. Prescription approval is required.
Disclosure: This site may receive compensation from NexLife or other partners. Compounded medications are not FDA-approved. Provider review and prescription approval are required.
Compounded tirzepatide and compounded semaglutide are not FDA-approved as finished drugs. They may be prescribed only when a licensed provider determines they are clinically appropriate and legally permissible for an individual patient. Brand-name medications such as Mounjaro, Zepbound, Ozempic, and Wegovy are FDA-approved products and should not be treated as identical to compounded medications.
Frequently asked questions
What should I compare first?
Compare total cost, dose increases, membership fees, provider review, pharmacy disclosure, shipping, and cancellation terms.
Can this tool determine eligibility?
No. Eligibility requires licensed provider review.
Sources
- FDA GLP-1 compounding policy clarification (Regulator)
- FDA Compounding and the FDA: Questions and Answers (Regulator)
- FDA 503B bulks list proposal for GLP-1 drugs (Regulator)
- Zepbound prescribing information (Label)
- Wegovy prescribing information (Label)
- NexLife tirzepatide pricing page (Provider pricing)
- NexLife FAQ pricing page (Provider pricing)
- NexLife semaglutide pricing page (Provider pricing)